{
    "clinical_study": {
        "@rank": "151432", 
        "acronym": "CAPS5", 
        "arm_group": [
            {
                "arm_group_label": "Familial pancreas cancer relatives", 
                "description": "High Risk Group 2 (familial pancreatic cancer relatives):\n> 55 years old or 10 years younger than the age of youngest relative with pancreatic cancer, and\ncome from a family with 2 or more members with a history of pancreatic cancer (2 of which have a first-degree relationship consistent with familial pancreatic cancer), and\nhave a first-degree relationship with at least one of the relatives with pancreatic cancer.\nIf there are 2 or more affected blood relatives, at least 1 must be a first-degree relative of the individual being screened"
            }, 
            {
                "arm_group_label": "Group 1 germline mutation carrier", 
                "description": "High Risk Group 3 (Group 1 germline mutation carriers with an associated with an estimated lifetime risk of pancreatic cancer of ~10% or higher):\na. > 50 years old or 10 years younger than the age of the youngest relative with pancreatic cancer, and b. The Patient is a carrier of a confirmed FAMMM (p16/CDKN2A), BRCA2, or PALB2 mutation, and there is > 1 pancreatic cancer in the family, one of whom is a first- or second-degree relative of the subject to be screened."
            }, 
            {
                "arm_group_label": "Group 2 germline mutation carrier", 
                "description": "High Risk Group 4 (Group 2 germline mutation carriers with an associated with an estimated lifetime risk of pancreatic cancer of ~5%):\n> 55 years old or 10 years younger than the age of the youngest relative with pancreatic cancer, and\nThe patient is a carrier of a confirmed BRCA1, or HNPCC (hereditary non-polyposis colorectal cancer or Lynch syndrome, hMLH1, hMSH2, PMS1, hMSH6, EpCAM) gene mutation, and there is > 1 pancreatic cancer in the family, one of whom is a first- or second-degree relative of the subject to be screened."
            }, 
            {
                "arm_group_label": "Hereditary pancreatitis", 
                "description": "High risk group 5 (hereditary pancreatitis) with confirmed gene mutations that predispose to chronic pancreatitis, such as PRSS1, PRSS2, CTRC) and age 50 years or older (these patients have an estimated lifetime risk for pancreatic cancer of 40%) or twenty-years since their first attack of pancreatitis, whichever age is younger."
            }, 
            {
                "arm_group_label": "Peutz-Jeghers Syndrome", 
                "description": "At least 30 years old, and\nat least 2 of 3 criteria diagnostic of Peutz-Jeghers syndrome (characteristic intestinal hamartomatous polyps, mucocutaneous melanin deposition, or family history of Peutz-Jeghers syndrome), or,\nknown STK11 gene mutation carrier"
            }, 
            {
                "arm_group_label": "Negative control", 
                "description": "are undergoing EUS and/or ERCP for non-pancreatic indications as part of their standard medical care, and\nhave no clinical or radiologic suspicion of pancreatic disease (chronic pancreatitis or pancreatic cancer)"
            }, 
            {
                "arm_group_label": "Chronic Pancreatitis", 
                "description": "are undergoing EUS and/or ERCP for  evaluation and/or treatment of suspected or proven chronic pancreatitis as part of their standard medical care, and,\nhave no clinical or radiologic suspicion of pancreatic cancer"
            }, 
            {
                "arm_group_label": "Pancreas cancer", 
                "description": "a. are undergoing EUS and/or ERCP for evaluation and/or treatment of suspected or proven pancreatic ductal adenocarcinoma (based on clinical and radiologic evidence)"
            }, 
            {
                "arm_group_label": "Pancreas cyst, IPMN evaluation", 
                "description": "are undergoing EUS and/or ERCP for evaluation and/or treatment of suspected or proven pancreatic cancer precursor, intraductal papillary mucinous neoplasm (based on clinical presentation and radiologic or prior EUS or radiologic evidence of a dilated main pancreatic duct and/or pancreatic cystic lesion communicating with the pancreatic ductal system)."
            }
        ], 
        "biospec_descr": {
            "textblock": "approximately 40 ml of blood approximately  5-20 ml pancreas juice approximately 10 ml\n      saliva (optional) pancreas cyst fluid (if available)"
        }, 
        "biospec_retention": "Samples With DNA", 
        "brief_summary": {
            "textblock": "Johns Hopkins clinical research office quality assurance group will monitor and audit this\n      study at Johns Hopkins.  The Principal Investigator at each site will be responsible for\n      internal monitoring at their site."
        }, 
        "brief_title": "The Cancer of the Pancreas Screening-5 CAPS5)Study", 
        "completion_date": {
            "#text": "December 2023", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Pancreas Cancer", 
            "Peutz-Jeghers Syndrome", 
            "Gene Mutation", 
            "Germline Mutation Carrier", 
            "Lynch Syndrome"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Pancreatic Neoplasms", 
                "Peutz-Jeghers Syndrome", 
                "Colorectal Neoplasms, Hereditary Nonpolyposis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Hereditary Pancreatitis or\n\n          -  Peutz-Jeghers Syndrome or\n\n          -  Strong family history of pancreas cancer on one side of the family tree or\n\n          -  Confirmed germline mutation carrier (BRCA2, FAMMM, PALB2, BRCA1, HNPCC, PRSS1/2, or\n             CTRC\n\n          -  Endoscopic evaluation of pancreas scheduled\n\n        Exclusion Criteria:\n\n          -  Medical comorbidities or coagulopathy that contraindicate endoscopy\n\n          -  Prior surgery that prevent optimal endoscopic ultrasound such as partial or complete\n             gastrectomy with Bilroth or Roux-en-Y anastomosis\n\n          -  Stricture or obstruction in the upper GI tract that does not allow passage of the\n             echoendoscope\n\n          -  Poor performance status\n\n          -  Inability to provide informed consent\n\n          -  Pregnancy."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Individuals at elevated risk for developing pancreas cancer"
            }
        }, 
        "enrollment": {
            "#text": "2500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 26, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02000089", 
            "org_study_id": "NA_00087754"
        }, 
        "intervention": {
            "arm_group_label": [
                "Familial pancreas cancer relatives", 
                "Group 1 germline mutation carrier", 
                "Group 2 germline mutation carrier", 
                "Hereditary pancreatitis", 
                "Peutz-Jeghers Syndrome", 
                "Negative control", 
                "Chronic Pancreatitis", 
                "Pancreas cancer", 
                "Pancreas cyst, IPMN evaluation"
            ], 
            "description": "I.V. bolus of 0.2 mcg/kg secretin given to induce pancreas juice secretion.  This intervention offered for all cohorts", 
            "intervention_name": "Human synthetic secretin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Pancreatin", 
                "Pancrelipase", 
                "Secretin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "familial pancreas cancer", 
            "PJS", 
            "BRCA2", 
            "PALB2", 
            "FAMMM", 
            "p16", 
            "BRCA1", 
            "HNPCC", 
            "Lynch Syndrome", 
            "hereditary pancreatitis", 
            "PRSS", 
            "CTRC"
        ], 
        "lastchanged_date": "May 28, 2014", 
        "location": [
            {
                "contact": {
                    "email": "james.j.farrell@yale.edu", 
                    "last_name": "James Farrell, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "New Haven", 
                        "country": "United States", 
                        "state": "Connecticut"
                    }, 
                    "name": "Yale University"
                }, 
                "investigator": {
                    "last_name": "James Farrell, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "hcosby1@jhmi.edu", 
                    "last_name": "Hilary Cosby, RN, CGRN", 
                    "phone": "410-502-2893"
                }, 
                "facility": {
                    "address": {
                        "city": "Baltimore", 
                        "country": "United States", 
                        "state": "Maryland", 
                        "zip": "21287"
                    }, 
                    "name": "Johns Hopkins Hospital"
                }, 
                "investigator": {
                    "last_name": "Michael Goggins, MD", 
                    "role": "Principal Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "sapna_syngal@dfci.harvard.edu", 
                    "last_name": "Sapna Syngal, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts"
                    }, 
                    "name": "Dana Farber Cancer Center, Harvard University"
                }, 
                "investigator": {
                    "last_name": "Sapna Syngal, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "arhim@med.umich.edu", 
                    "last_name": "Andrew Rhim, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Ann Arbor", 
                        "country": "United States", 
                        "state": "Michigan"
                    }, 
                    "name": "University of Michigan"
                }, 
                "investigator": {
                    "last_name": "Andrew Rhim, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "fk18@cumc.columbia.edu", 
                    "last_name": "Kay Kastrinos, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "New York City", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10032"
                    }, 
                    "name": "Columbia University Medical Center"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "amitabh.chak@uhhospitals.org", 
                    "last_name": "Amitabh Chak, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Cleveland", 
                        "country": "United States", 
                        "state": "Ohio"
                    }, 
                    "name": "Case Comprehensive Cancer Center, Case Western Medical Reserve"
                }, 
                "investigator": {
                    "last_name": "Amitabh Chak, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "anil2@mail.med.upenn.edu", 
                    "last_name": "Anil Rustgi, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Philadelphia", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }, 
                    "name": "University of Pennsylvania"
                }, 
                "investigator": {
                    "last_name": "Anil Rustgi, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "email": "brandre@upmc.edu", 
                    "last_name": "Randy Brand, MD"
                }, 
                "facility": {
                    "address": {
                        "city": "Pittsburgh", 
                        "country": "United States", 
                        "state": "Pennsylvania"
                    }, 
                    "name": "University of Pittsburgh"
                }, 
                "investigator": {
                    "last_name": "Randy Brand, MD", 
                    "role": "Sub-Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "9", 
        "official_title": "The Cancer of the Pancreas Screening-5 CAPS5)Study", 
        "other_outcome": {
            "description": "Aim #3: To determine the prevalence of pancreatic lesions, pancreatic fluid mutations and circulating pancreatic epithelial cells among a large cohort of high-risk individuals undergoing pancreatic screening and surveillance of a new cohort in which screening is begun at age >55.", 
            "measure": "Time disease progression and prevalence", 
            "safety_issue": "No", 
            "time_frame": "8 years"
        }, 
        "overall_contact": {
            "email": "hcosby1@jhmi.edu", 
            "last_name": "Hilary Cosby, RN"
        }, 
        "overall_official": {
            "affiliation": "Johns Hopkins University", 
            "last_name": "Michael Goggins, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2021", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Aim #1: To evaluate pancreatic fluid mutations and circulating pancreatic epithelial cells as accurate markers of neoplasia by comparing their prevalence in cases with sporadic pancreatic neoplasia to healthy and disease controls.", 
            "measure": "Evaluate pancreatic juice for early cancer markers.", 
            "safety_issue": "No", 
            "time_frame": "8 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02000089"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Johns Hopkins University", 
            "investigator_full_name": "Michael Goggins, MD", 
            "investigator_title": "Professor of Medicine, Pathology and Gastroenterology", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Aim #2: To compare the prevalence of pancreatic fluid mutations and circulating pancreatic epithelial cells among a prospective cohort of individuals with sporadic pancreatic cysts undergoing pancreatic surveillance.", 
            "measure": "Compare pancreas juice with pancreas cyst fluid", 
            "safety_issue": "No", 
            "time_frame": "8 years"
        }, 
        "source": "Johns Hopkins University", 
        "sponsors": {
            "collaborator": {
                "agency": "ChiRhoClin, Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Johns Hopkins University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}